BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.